CLDN1 was demonstrated to cause chemoresistance in CRC via upregulating ephrin type-A receptor 2 (EPHA2) tyrosine kinase, which enhances downstream the AKT signaling pathway, and CD44 expression, which promotes cancer stemness and chemoresistance [62]. The gene discussed is EPHA2; the disease is cancer.